Tafinlar Novartis Pharmaceuticals Australia Pty Ltd

TAFINLAR (dabrafenib), used together with trametinib, is proposed as a treatment for adults with a type of thyroid cancer called differentiated thyroid cancer (with a change in the BRAF V600E gene) that has spread or cannot be removed with surgery.
It is proposed for patients that do not respond to radioactive iodine treatment, or cannot receive it, and whose cancer has continued to progress after previous treatments